Challenges in urine bioanalytical assays: overcoming nonspecific binding. (September 2010)

• Record Type: Journal Article
• Authors: Ji, Allena Ji; Jiang, Zhiping; Livson, Yuliya; Davis, Jennifer Ann; Chu, Jasper Xuegong; Weng, Naidong
• Is Part Of: Bioanalysis. Volume 2:Number 9(2010)
• Page Start: 1573
• Page End: 1586
• Publication Date: 2010-09
• Subjects: Drugs -- Analysis -- Periodicals; 615.19005
• DOI: 10.4155/bio.10.114
• Languages: English
• ISSNs: 1757-6180

Abstract

Dr Allena Ji is the Director of Bioanalytical Services, XenoBiotic Laboratories, Inc., NJ, USA. She has worked in the bioanalytical field for many years and accumulated rich experience in LC–MS/MS method development, method validation and sample analysis under GLP compliance in large pharmaceutical company and contract laboratory settings. In the past 10 years, Allena worked at Pfizer (Legacy of Wyeth) and investigated many small-molecule drug candidates for their nonspecific binding in urine assays. Nonspecific binding of compounds results in a severe underestimation of the compounds' concentrations and poor precision and accuracy in urine bioanalytical assays. To overcome nonspecific binding in urine assays, Allena and her colleagues developed a series of practical approaches for urine method development. By adding an appropriate anti-adsorptive agent at its optimum concentration to the urine collection containers, the nonspecific binding can be blocked. Urine assays have much higher hurdles than plasma assays due to nonspecific binding and variability of urine pH, salt concentration, volume and solubility of drug(s) in urine. A simple and systematic approach for urine method development is emphasized in this paper. Nonspecific binding is a very serious issue in bioanalytical urine assays where a compound(s) adsorbs to the container wall. The adsorption happens frequently in urine assays because urine lacks proteins and lipids that can bind to the analytes or solubilize lipophilic analytes. Therefore, urine bioanalytical assays tend to suffer from analyte losses more often than plasma assays. In the past decade, there have been many methods described to overcome nonspecific adsorption in urine assays based on individual analyte characteristics. However, a common and simple method development approach for various analytes has not been discussed and summarized. In this article we demonstrate, discuss and summarize a common approach to urine method development with a focus on overcoming adsorption issues. The advantages and limitations of commonly used anti-adsorptive agents, such as bovine serum albumin, zwitterionic detergents such as CHAPS, sodium dodecyl benzene sulfonate, β-cyclodextrin, Tween 80 and Tween 20 are discussed.